Truist analyst Gregory Renza initiated coverage of CG Oncology (CGON) with a Buy rating and $62 price target The firm views Creto’s high complete response rates, favorable tolerability, and differentiated durability as key attributes that could support robust market positioning for the company, the analyst tells investors in a research note. The potential expansion into intermediate-risk/IR NMIBC, or Non-Muscle Invasive Bladder Cancer, and additional high-risk settings represent a strategic approach that could broaden Creto’s commercial opportunity, given the ongoing BCG – Bacillus Calmette Guerin – shortage, Truist added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $61 from $53 at RBC Capital
- CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation
- Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.
- CG Oncology Advances Bladder Cancer Therapy Development
- CG Oncology Appoints Jim DeTore as Interim CFO